Table 1 Reported cases of pseudomyogenic hemangioendothelioma
From: Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma
References | Cases (N) | Sex | Tumor location | Multifocality at diagnosis | Management |
|---|---|---|---|---|---|
Sheng [1] | 1 | Male: 100 % (1of 1) Female: 0 % (0 of 1) | Extremity: 100 % (1 of 1) | 100 % (1 of 1) | Excision: 100 % (1 of 1) |
Hornick and Fletcher [2] | 50 | Male: 82 % (41 of 50) Female: 18 % (9 of 50) | Extremity: 78 % (39 of 50) Trunk: 18 % (9 of 50) Head and neck: 4 % (2 of 50) | 66 % (33 of 50) | Excision: 92 % (46 of 50) Post-operative radiation: 16 % (8 of 50) Chemotherapy: 12 % (6 of 50) |
Amary et al. [5] | 5 (1 case included in Hornick was excluded)a | Male: 50 % (2 of 4) Female: 50 % (2 of 4) | Extremity: 100 % (4 of 4) | 75 % (3 of 4) | Excision: 75 % (3of 4) Chemotherapy: 25 % (1 of 4) |
Stuart et al. [7] | 1 | Male: 100 % (1 of 1) Female: 0 % (0 of 1) | Extremity: 100 % (1 of 1) | 100 % (1 of 1) | Chemotherapy: 100 % (1 of 1) |
Sheng and Wang [9] | 1 | Male: 0 % (0 of 1) Female: 100 % (1 of 1) | Extremity: 100 % (1 of 1) | 100 % (1 of 1) | Excision: 100 % (1 of 1) |
Requena et al. [10] | 2 | Male: 50 % (1 of 2) Female: 50 % (1 of 2) | Extremity: 50 % (1 of 2) Head and neck: 50 % (1 of 2) | 100 % (2 of 2) | Excision: 100 % (2 of 2) |
Righi [11] | 2 | Male: 50 % (1 of 2) Female: 50 % (1 of 2) | Extremity: 100 % (2 of 2) | 100 % (2 of 2) | Excision: 100 % (2 of 2) |
Karakasli et al. [12] | 1 | Male: 100 % (1 of 1) | Extremity: 100 % (1 of 1) | 0 % (0 of 1) | Excision: 100 % (1 of 1) |
McGinity [13] | 1 | Male: 100 % (1 of 1) Female: 0 % (0 of 1) | Extremity: 0 % (0 of 1) Trunk: 100 % (1 of 1) | 0 % (0 of 1) | Excision: 100 % (1 of 1) |
Total | 63 | Male: 78 % (49 of 63) Female: 22 % (14 of 63) | Extremity: 79 % (50 of 63) Trunk: 16 % (10 of 63) Head and neck: 5 % (3 of 63) | Multifocality at diagnosis: 68 % (43 of 63) | Excision: 90 % (57 of 63) Post-op radiation: 13 % (8 of 63) Chemotherapy: 13 % (8 of 63) |